Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J; CLEOPATRA study group. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 21: 519-530, 2020. PMID: 32171426.
Yanai K, Fujii T, Horiguchi J, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R, Shirabe K. Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer. BMC Cancer. 20: 1068, 2020. PMID: 33158432.
Kurozumi S, Alsaleem M, Monteiro CJ, Bhardwaj K, Joosten SEP, Fujii T, Shirabe K, Green AR, Ellis IO, Rakha EA, Mongan NP, Heery DM, Zwart W, Oesterreich S, Johnston SJ. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. Breast Cancer Res. 22: 85, 2020. PMID: 32782013.
Nakazawa Y, Nakazawa S, Kurozumi S, Ogino M, Koibuchi Y, Odawara H, Oyama T, Horiguchi J, Fujii T, Shirabe K. The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy. Oncol Lett. 19: 2705-2712, 2020. PMID: 32218821.
Toda H, Seki N, Kurozumi S, Shinden Y, Yamada Y, Nohata N, Moriya S, Idichi T, Maemura K, Fujii T, Horiguchi J, Kijima Y, Natsugoe S. RNA-sequence-based microRNA expression signature in breast cancer: tumor-suppressive miR-101-5p regulates molecular pathogenesis. Mol Oncol. 14: 426-446, 2020. PMID: 31755218.
Kurozumi S, Inoue K, Matsumoto H, Fujii T, Horiguchi J, Oyama T, Kurosumi M, Shirabe K. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. Sci Rep. 9: 16662, 2019. PMID: 31723167.
Sekine C, Kawase K, Yoshida K. Sentinel lymph node biopsy of primary apocrine sweat gland carcinoma of the axilla: a case report and review of the literature. Int J Surg Case Rep. 77: 122-125, 2020. PMID: 33160170.
Ogino M, Fujii T, Nakazawa Y, Higuchi T, Koibuchi Y, Oyama T, Horiguchi J, Shirabe K. Implications of Topoisomerase (TOP1 and TOP2α) Expression in Patients With Breast Cancer. In Vivo. 34: 3483-3487, 2020. PMID: 33144457.
